Table 1 Clinical benefits and incremental cost-effectiveness ratios by vaccine coverage and cost per-vaccinated individuala

From: The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting

  

Cost per-vaccinated individual c

 

Reduction in lifetime cancer riskb %

$25 ($5 per dose)

$50 ($12 per dose)

$100 ($27 per dose)

$400 ($115 per dose)

25% coverage

 Girls only

14

Cost-savingd

70

610

3450

 Girls and boys

21

110

810

2190

9370

50% coverage

 Girls only

29

Cost-savingd

30

540

3210

 Girls and boys

40

660

1740

3900

15 120

75% coverage

 Girls only

45

Cost-savingd

130

740

3940

 Girls and boys

57

2440

2180

4860

18 820

90% coverage

 Girls only

63

Cost-savingd

170

810

4180

 Girls and boys

67

9110

18 650

37 720

136 910

  1. Values represent incremental cost-effectiveness ratios (additional cost divided by additional health benefit compared to the next best strategy) expressed as cost per year of life saved (international dollar per YLS). Strategies including girls alone were compared to no vaccination.
  2. bReduction in lifetime cancer risk for all strategies was calculated against no vaccination.
  3. cCost per-vaccinated individual includes three doses, wastage, delivery, and programmatic costs, and is expressed in 2000 international dollars.
  4. dStrategies are cost-saving compared to no vaccination because the future costs averted by preventing cancer are greater than the cost of vaccination.
Back to article page